Biotech in the Balance: Saving a Strategic Industry. Jeremy Levin on The Long Run

Jeremy Levin is today’s guest on The Long Run.

He is the executive chairman and founder of New York-based Ovid Therapeutics. He’s also a board member of the Biotechnology Innovation Organization, and a past chairman of the BIO board of directors.

Jeremy has a new book out today, called “Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust.” It’s for biotech executives, policymakers, or any curious citizen interested in how we better harness biotechnology for the betterment of the maximum number of people around the world. 

This book is not just a laundry list of what’s wrong with the industry or the public. It contains 10 commitments. These are practical suggestions of things companies can do to make for a healthier industry, and to help create a more stable, thriving industry that earns more public support.  

I hope you enjoy this conversation, and that it might help serve as a conversation starter in your circles.

The Long Run is sponsored by:

 

 

AlphaSense is an AI-powered market intelligence platform designed to help investors and operators find critical insights faster. Think of it as a search engine for the entire financial and life sciences landscape, aggregating over 500 million documents across company filings, clinical trial registries, FDA documents, earnings calls, expert transcripts, broker research, and industry publications into one unified, searchable platform.

For those researching biotech, medtech, and the broader life sciences landscape, it is a game-changer, purpose-built to surface the clinical, regulatory, and commercial insights that matter most.  You can use Smart Summaries to instantly synthesize thousands of pages of trial data, regulatory filings, and KOL commentary, while Channel Checks and expert insights help you understand how therapies are actually being adopted in the real world across physicians, payers, and hospital systems, not just how they are modeled on paper.

Instead of spending hours digging through 10-Ks, AlphaSense surfaces the ‘Alpha’—the specific insights that move the needle—in seconds.  To experience it firsthand, you can start a free trial at alpha-sense.com/thelongrun.

 

Bioanalysis should not rely on which scientists at the CRO you get. These are assays, not consulting. Your results should be the same, regardless of who does the work.

“We love working with our CRO… when we get the right PI” is a red flag, not a compliment. And if the quality of your bioanalysis depends on which principal investigator happens to be assigned to your study, you don’t have a CRO partnership, you have a lottery ticket.

Dash was built around automation and standardized workflows specifically to eliminate that variability. Every study gets the same rigor and the same rapid turnaround, days not weeks, across ELISA/MSD, LC-MS, and PCR. GLP-compliant, transparent pricing, guaranteed outcomes. You shouldn’t have to ask who’s running your study. You should just get great data.

Visit www.dash.bio

Now please enjoy this conversation with Jeremy Levin on The Long Run.